Andson Biotech raises $3.6 million seed round

Andson Biotech logo

ATLANTA, April 30, 2024  –  Andson Biotech , a biotools company developing streamlined sample prep and data analytics solutions for mass spectrometry workflows, has successfully closed a $3.6 million round in equity financing. This capital will support hiring talent to accelerate the market introduction of its inline mass spec sample prep solution,  DynaCHIP . This patented technology seamlessly integrates into existing mass spec workflows, significantly reducing sample prep times. In addition, Andson will deploy funds to develop  DynaMARK , a novel analytics tool that supports emerging cell and gene therapy applications.

“This financing round signifies a significant milestone for  Andson Biotech , demonstrating our commitment to making mass spectrometry more productive for current and next-gen biotherapeutics,”says  CEO and Co-Founder, Mason Chilmonczyk . “We are grateful for the support of investors and advisors who have built successful biotech companies in the past as we embark on this next phase of growth.”

The round was led by  Glenn H. Epstein , an investor with a successful track record in funding and advising multiple companies from early-stage formation to robust sales growth from products and services. He will serve on Andson’s board of directors.

“Andson has made significant technical progress since its inception at  Georgia Tech  in early 2022,” says  Tom O’Brien ,  Executive Chairman  of the board at  Andson Biotech . “Having collaborated closely with the Andson team for the past year, I am confident in their capabilities and vision. More importantly, I am optimistic about the impact Andson’s products will have in the biotools market.”

‍ About Andson Biotech

‍ Headquartered in Atlanta, GA,  Andson Biotech  specializes in providing cutting-edge solutions for mass spectrometry, the gold standard for chemical analysis. At the forefront of its offerings is the  DynaCHIP , a hardware system designed to enhance mass spec workflows, delivering productivity gains of up to 100x.

Andson Biotech’s  initial technology was licensed from  Georgia Tech .  The Company received early financial support from the  Georgia Research Alliance (GRA)  and  Biolocity . Subsequent support from entities like  Y Combinator  (Winter, 2022), the  Merck Digital Sciences Studio  (Inaugural Cohort ‘23), and  BioTools Innovator  (2023 Finalist) have further propelled the company’s growth, bringing its total funding to over $5 million since January 2022.

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS